Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while another drugmaker entered the market with a much more modest discount to the branded medicine's list price.
July 1 - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s
The copycat drug called Hadlima will be listed at $1,038 per month, representing an 85% discount of Humira’s current $6,922 monthly price, the companies said. Unlike pills, which have extremely cheap generic copies, complex, expensive biologic drugs made from living cells cannot be exactly duplicated. Their closest alternatives are called biosimilars.
Three PBMs -- CVS Health Corp , Cigna Group's Express Scripts and UnitedHealth Group's Optum RX -- together control 80% of the U.S. prescription drug market.to appeal to pharmacy benefit managers. Some of their fees are a percentage of the savings they negotiate and the PBMs are expected to win significant discounts from the announced prices for health plans.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Leer más »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Leer más »
For AbbVie’s blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayLower-price biosimilar competition for top-selling drug launching this weekend.
Leer más »
Humira, the world’s top-selling drug, faces an upcoming test from low cost alternativesNew Humira alternatives will be available in July. This could make the drug that now costs nearly $80,000 per year more affordable.
Leer más »
Will lower-cost Humira pharmaceutical options soon be available to patients?Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big...
Leer más »
Sandoz launches rival version of AbbVie's arthritis drug HumiraSwiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January.
Leer más »